Glioblastomas are lethal cancers defined by angiogenesis and pseudopalisading necrosis. Here, we demonstrate that these histological features are associated with distinct transcriptional programs, with vascular regions showing a proneural profile, and hypoxic regions showing a mesenchymal pattern. As these regions harbor glioma stem cells (GSCs), we investigated the epigenetic regulation of these two niches. Proneural, perivascular GSCs activated EZH2, whereas mesenchymal GSCs in hypoxic regions expressed BMI1 protein, which promoted cellular survival under stress due to downregulation of the E3 ligase RNF144A. Using both genetic and pharmacologic inhibition, we found that proneural GSCs are preferentially sensitive to EZH2 disruption, whereas mesenchymal GSCs are more sensitive to BMI1 inhibition. Given that glioblastomas contain both proneural and mesenchymal GSCs, combined EZH2 and BMI1 targeting proved more effective than either agent alone both in culture and in vivo, suggesting that strategies that simultaneously target multiple epigenetic regulators within glioblastomas may be effective in overcoming therapy resistance caused by intratumoral heterogeneity.
Glioblastoma is the most prevalent and lethal primary brain tumor, with current therapies offering only palliation 1 . Glioblastomas represent one of the most rigorously characterized solid cancers, yet delineation of molecular lesions has not translated into effective targeted therapeutics. Glioblastomas display remarkable heterogeneity, both between tumors (intertumoral heterogeneity) and within tumors (intratumoral and cellular heterogeneity), indicating a molecular and cellular complexity that is unlikely to respond to targeting of single molecular pathways. Glioblastomas contain stem cell-like tumor -initiating cells called GSCs (also known as cancer stem cells) 2, 3 . Whereas the definition and origin of GSCs are unresolved, their significance has been supported by observations that they promote resistance to conventional therapies, invasion into normal brain and angiogenesis [4] [5] [6] . GSCs are not uniformly distributed within tumors but rather are enriched in perivascular and hypoxic niches, suggesting that GSCs critically interact with their microenvironment [6] [7] [8] . Indeed, microenvironmental stressors, such as hypoxia, acid and nutrient restriction, promote GSC maintenance 7, 9, 10 .
Global transcript profiling and DNA methylation analyses from bulk adult glioblastoma samples have categorized glioblastoma into several distinct subtypes: glioma CpG island methylator phenotype (G-CIMP), which is associated with mutations in the genes encoding isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2); non-G-CIMP proneural; classical or proliferative; and mesenchymal 11 . Genomic profiling has not been able to guide precision medicine efforts for glioblastoma 12 , possibly because the tumors comprise cell populations with divergent subtype-specific gene expression 13, 14 . Glioblastoma transcriptional groups, including a tendency toward proneuralto-mesenchymal transition after cytotoxic therapy, are plastic 15, 16 . Nevertheless, tumor cells grown under stem cell conditions recapitulate the dominant subtype of the parental tumor, suggesting retention of a cell-intrinsic biology 17, 18 . We hypothesized that the heterogeneous distribution of GSCs suggests that they reside in different niches, requiring differential therapeutic targeting of different subsets in the context of their specific niches.
RESULTS
As bulk tumors contain cells from different subgroups 13 , we profiled expression patterns within specific tumor microenvironments by image-guided multiregional glioblastoma sampling (Fig. 1a) . Tumor cells from the enhancing region (ER), defined by disruption of the blood-brain barrier at areas of angiogenesis, showed high expression of proneural genes, whereas the necrotic region (NR; hypoxic) show high expression of mesenchymal genes (Fig. 1b) . An intermediate tumor region (enhanced margin, EM) displayed a mixed transcriptional signature comprising classical and proneural gene expression signatures (Fig. 1b) . These findings were validated in two other multiregional patient biopsies with glioblastoma subtype gene signatures (Supplementary Fig. 1 ). GSCs displayed regional variation, measured by immunofluorescence of each region using the proneural GSC markers SOX2 and OLIG2 and the mesenchymal GSC markers CD44 and YKL40 (refs. 16,19) . GSCs in the ER were exclusively SOX2 + and OLIG2 + , whereas NR GSCs were exclusively CD44 + and YKL40 + , indicating segregation of proneural and mesenchymal GSC markers (Fig. 1c) . Gene expression profiling for vascular and hypoxic markers confirmed that proneural-enriched cells were associated with vascular regions, and mesenchymal cells, with hypoxia (Fig. 1d) . Immunofluorescence staining using von Willebrand factor (vWF) for vessels and carbonic anhydrase 9 (CA9) for hypoxia confirmed the regional variance of vascularity and hypoxia (Fig. 1e) . To validate our observations in a larger tumor cohort, we interrogated the Ivy Glioblastoma Atlas Project (Ivy GAP) database, which contains data from 42 glioblastomas regionally microdissected with RNA-seq (http://glioblastoma.alleninstitute.org/). Confirming our findings from the MRI-guided biopsy results, the leading edge and infiltrating tumor regions expressed a proneural signature, whereas perinecrotic and microvascular proliferative regions expressed a mesenchymal signature ( Fig. 1f-h) .
Next, we constructed microenvironment-related gene signatures based on microarray data from vascular sources (human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC)) and analyses comparing glioblastoma hypoxia to normoxia 20, 21 ( Supplementary Figs. 2a,b and 3a,b) . Selected signatures and genes were analyzed in glioblastoma samples and the Ivy GAP database (Supplementary Figs. 2c ,f,i and 3c,f). In The Cancer Genome Atlas (TCGA) low-grade glioma-glioblastoma database, both vascular signatures and hypoxia were expressed in glioblastoma ( Supplementary Figs. 2d,g and 3d) and associated with tumor histology, grade and defining molecular features (Supplementary Fig. 4a ). Proneural glioblastomas expressed markers of mature vessels, whereas mesenchymal glioblastomas expressed markers for microvasculature and hypoxia 22, 23 ( Supplementary Figs. 2e,h and 3e) . Both vascular signatures and hypoxia were anticorrelated with patient survival (Supplementary Figs. 2j,k and 3g) . Patients with both vascularity and hypoxic expression patterns fared the worst (Supplementary Fig. 4b ), supporting microvascular and hypoxic microenvironments as major predictors of unfavorable glioblastoma patient survival 24, 25 . Our multiregional patient biopsy samples validated these in silico observations, demonstrating that the regional variation in transcriptional signatures correlated with vascular and hypoxic features ( Supplementary  Fig. 4c,d) .
Regional transcriptional variation may reflect differences in chromatin regulation. Polycomb repressive complexes (PRCs) comprise major chromatin modifiers of epigenetic regulation of global gene expression. PRC1 and PRC2 regulate chromatin compaction through specific histone modifications: PRC2 first binds to chromatin and its catalytic subunit, EZH2, trimethylates histone H3 at residue K27 (H3K27me3). H3K27me3 is then recognized by PRC1, which contains BMI1, then monoubiquitination of histone 2A on K119 (H2AK119Ub) causes chromatin compaction and pausing of RNA polymerase II. However, recent evidence suggests that PRC1 can also silence gene expression through a noncanonical, H3K27me3 -independent mechanism 26 . Given this background, we investigated PRC1 and PRC2 activity with H2AK119Ub and H3K27me3 staining in multiregional patient biopsy samples, observing dichotomous distribution of cells positive for H2AK119Ub and H3K27me3 in hypoxic (necrotic) and vascular (enhancing) regions, respectively ( Fig. 2a and  Supplementary Fig. 5a ). As the GSC markers CD133 and CD44 may be specific for glioblastoma subgroup 16 , we employed another GSC marker, CD15 (also known as SSEA1) 27 , which was less specific but more sensitive than CD133 (data not shown). CD15 + cells in different regions expressed H2AK119Ub or H3K27me3 and displayed functional characteristics of GSCs ( Fig. 2a and Supplementary  Fig. 5a-c) . Using image-guided biopsies from two glioblastomas, we interrogated genome-wide distribution of chromatin marks from PRC1 (H2AK119Ub) 28 or PRC2 (H3K27me3) in CD15 + GSCs from enhancing and necrotic regions using chromatin immunoprecipitation followed by deep sequencing (ChIP-seq). To determine regionspecific peaks, we analyzed overlapping peaks in both samples and identified peaks that were both unique to a particular anatomic region and were shared between the samples (Fig. 2b) . Annotation of region-specific genes marked by H3K27me3 or H2AK119Ub in the same anatomic region from both patients revealed that more than 80% of region-specific target genes displayed differential H3K27me3 or H2AK119Ub marks ( Fig. 2c and Supplementary Table 1 ), indicating distinct PRC function in GSCs residing in different regions. While intertumoral variation was substantial, shared regions converged on important gene targets. H3K27me3, generally associated with inhibition of transcription, marked neuronal and cellular development targets in both the ER and NR, albeit without substantial overlap in gene identity, with EZH2, SUZ12 and H3K27me3 targets most significantly marked by H3K27me3 in the ER (Fig. 2d and Supplementary Table 1 ). In contrast, H2AK119Ub marked very different targets in the ER and NR, with H2AK119Ub in CD15 + GSCs from the hypoxic regions marking genes strongly associated with mesenchymal signaling pathways, such as those encoding transforming growth factor-β (TGF-β), nuclear factor-κB (NF-κB) and WNT ( Fig. 2d and Supplementary Table 1) , indicating probable microenvironment-specific functions of PRC2 and PRC1. Furthermore, tumors with proneural signatures showed enrichment of an EZH2 activation signature (containing 41 putative targets or partners of EZH2) 29 ( Fig. 2e and Supplementary Fig. 6g ), whereas tumors with mesenchymal transcriptional profiles showed enrichment of a BMI1 activation signature (containing 341 genes downregulated upon BMI1 knockdown) 30 ( Fig. 2f and Supplementary Fig. 7g ). Using a glioblastoma tumor microarray, we confirmed the correlation of high EZH2 protein levels with high expression of OLIG2, a proneural marker, and high BMI1 protein levels with high expression of CD44, a mesenchymal marker (Fig. 3a) .
To assess PRC contribution to microenvironment-specific distribution of glioblastoma subtypes, we correlated EZH2, BMI1 and microenvironment-related signatures. The EZH2 activation signature positively correlated with proneural and mature vascular signature but negatively correlated with mesenchymal and classical microenvironment signatures (Supplementary Figs. 6f and 8b,c) , implicating EZH2 function in tumor neovascular regions 31 . Conversely, a BMI1 activation signature correlated positively with mesenchymal or classical microenvironment signatures and negatively with a proneural microenvironment signature (Supplementary Figs. 7f and 8b,c) . EZH2 and BMI1 expression or activation signatures were associated with poor patient prognosis, but the worst prognosis was associated with high expression of both proteins or signatures ( Fig. 3b and Supplementary Figs. 6e,h,i, 7e,h and 8a,d) , suggesting that combined PRC1-PRC2 activation portends greater tumor malignancy. As both EZH2 and BMI1 regulate GSCs, we investigated BMI1 and EZH2 expression in several validated proneural and mesenchymal GSC and neural progenitor cell models. BMI1 and H2AK119Ub were markedly increased in CD44 + and YKL40 + mesenchymal GSCs, whereas EZH2 and H3K27me3 were associated with OLIG2 + and SOX2 + proneural GSCs (Fig. 3c) . RNA-seq data from 19 patientderived GSC models that we generated confirmed that EZH2 mRNA and activity signatures correlated with a proneural signature, whereas BMI1 activation, but not BMI1 mRNA, correlated with mesenchymal GSCs (Supplementary Fig. 9 ), indicating that BMI1 and EZH2 signaling pathways were activated in different GSC subtypes.
EZH2 mRNA expression levels correlated with the EZH2 activation signature and the proneural subtype and microenvironment in TCGA tumor samples (Supplementary Fig. 6 ), but we were surprised to find that BMI1 mRNA expression did not correlate with a BMI1 activation signature or the mesenchymal subtype or microenvironment signature (Supplementary Fig. 7 ), suggesting that EZH2 is regulated at the transcriptional level but BMI1 is regulated posttranscriptionally. Inhibiting translation with cycloheximide treatment showed that BMI1 protein levels were unchanged in mesenchymal GSCs but markedly reduced in proneural GSCs ( Supplementary  Fig. 10a ). Conversely, polyubiquitinated BMI1 was strongly increased in proneural GSCs after treatment with the proteasome inhibitor lactacystin but weakly accumulated in mesenchymal GSCs under the same conditions (Fig. 3d) , suggesting that ubiquitin-mediated proteolysis maintains BMI1 protein stability in GSCs of different subtypes. On the basis of the apparent region-specific BMI1 proteosomal degradation, we interrogated the TCGA glioblastoma database for ubiquitin-related genes whose expression correlated inversely with BMI1 activation. Among 254 genes associated with ubiquitination, 22 were differentially expressed by proneural and mesenchymal glioblastomas (Supplementary Fig. 10b ). To link these genes to BMI1 activity, we plotted r values for the 22 genes against two BMI1-related signatures (Fig. 3e) . The highest r value negatively associated with BMI1 activation was associated with the ring finger, RNF144A, which was previously described as an E3 ligase for DNAdependent protein kinase, catalytic subunit DNA-PKcs 32 . Supporting its potential role as a BMI1 E3 ligase, RNF144A expression negatively correlated with BMI1 activation and positively correlated with a BMI1 inhibition signature (Fig. 3e) . The results from ChIP-seq for BMI1, RNF144A and tubulin were analyzed by immunoblot in the input (whole-cell lysates). (g) Levels of RNF144A, BMI1, EZH2, CD44, YKL40, OLIG2 and SOX2 measured by immunoblot in neural progenitor cells (NPC1), proneural GSCs (PN1919 and PN3691) and mesenchymal GSCs (MES20 and MES28) grown under baseline conditions or in low-glucose and/or hypoxic conditions. (h) Viability NPC1 cells, proneural GSCs (PN11, PN23, PN1919 and PN3691) and mesenchymal GSCs (MES20, MES28, MES3565 and MES738) determined under baseline conditions or in low-glucose and/or hypoxic conditions. Data are as mean ± s.e.m. *P < 0.05, Wilcoxon and Mann-Whitney t-test.
acetylation of K27 on histone H3 (H3K27ac) on a panel of glioma GSCs and primary patient glioblastoma tissues with proneural or mesenchymal signatures were then compared to results deposited for other gliomas and normal brain. CD44 showed preferential activation, measured by H3K27ac deposition, in mesenchymal models, whereas OLIG2 was more specific for proneural tumors (Supplementary Fig. 10c ). RNF144A transcriptional regulation was stronger in proneural models and its promoter also bound SOX2, a proneural marker (Supplementary Fig. 10c ). Supporting a negative regulatory role of RNF144A on BMI1 protein levels, mesenchymal
GSCs showed lower expression of RNF144A protein than normal neural precursors and proneural GSCs (Supplementary Fig. 10d ).
Immunoprecipitation confirmed direct binding of RNF144A to BMI1 (Supplementary Fig. 10e ). Depleting RNF144A in proneural GSCs with low baseline levels of BMI1 reduced polyubiquitinated BMI1 after proteolysis inhibition and concordantly increased nonubiquitinated BMI1 protein expression (Fig. 3f) . Nonubiquitinated BMI1 protein in cells in which RNF144A was knocked down by small hairpin RNA (shRNA) persisted at similar levels with or without proteolysis inhibition (Supplementary Fig. 10f ), highlighting 
Relative RNF144A-mediated polyubiquitination as a regulatory node for BMI1 protein degradation.
To determine the clinical relevance of RNF144A in gliomas, we examined its regulation and survival in patient tissues and databases. RNF144A expression was lower in glioblastoma than low-grade glioma (LGG) and inversely related to patient survival ( Supplementary  Fig. 11a-d) . Using the LGG-glioblastoma TCGA data set, we mapped the expression of RNF144A and EZH2 mRNA against tumor histology, grade and common molecular features (IDH1 or ATRX mutations; chromosome 1p and 19q co-deletion) as well as patient survival (Supplementary Fig. 12a ). RNF144A mRNA expression showed a strong inverse correlation with glioblastoma histology and IDH1 mutation and a weaker association with chromosome 1p and 19q co-deletion. Tumors with low RNF144A and high EZH2 mRNA expression (RNF144A low EZH2 high ) were enriched with unfavorable microenvironmental transcriptional signatures (Supplementary Fig. 12b) . To determine the prognostic significance of RNF144A and EZH2 mRNA levels, we mapped expression levels for each targets and derived survival trends, which showed that RNF144A low EZH2 high tumors had the lowest survival (Supplementary Fig. 12c ). Multivariate analysis considering patient age, tumor grade and IDH mutation status revealed RNF144A mRNA and BMI1 activation signatures as independent prognostic factors for overall survival across all grades of glioma (Supplementary Table 2 ) but not glioblastoma (Supplementary Table 3 ). Collectively, these results show that suppression of RNF144A is associated with tumor grade and patient outcome, supporting a negative role in tumor malignancy.
To determine a functional role for differential PRC utilization by GSCs, we examined EZH2 and BMI1 expression in GSCs and neural precursors under stressful conditions, including hypoxia and nutrient restriction. Neural precursors and proneural GSCs lost BMI1 and EZH2 expression, with loss of proneural GSC markers (Fig. 3g) . In contrast, mesenchymal GSCs under stress showed no changes in BMI1 expression and increases in expression of mesenchymal markers . P values were determined by log-rank test. (f) Kaplan-Meier survival curves for mice bearing subtype-mixed orthotopic tumors (PN1919 and MES20) after combined treatment of 10 mg/kg BMI1-i once per week and 350 mg/kg EZH2-i thrice weekly (n = 8 per group). P values in e and f were determined by log-rank test.
( Fig. 3g) . Some mesenchymal GSCs remained viable under stress, whereas almost all neural precursors and proneural GSCs died (Fig. 3h) . Thus, stress conditions similar to those found in the pseudopalisading necrotic regions may select for mesenchymal glioma cells expressing BMI1 protein. Under low stress, RNF144A depletion in proneural GSCs increased BMI1 expression but did not alter cell proliferation or self-renewal, suggesting that BMI1 is not essential in the absence of stress (Supplementary Fig. 13a,b) . In contrast, targeting RNF144A expression in proneural GSCs under stress increased cell survival (Supplementary Fig. 13c ). To further assess PRC function under stress, we depleted either EZH2 or BMI1 using two nonoverlapping specific shRNAs for each target in two proneural and two mesenchymal early passage, patient-derived GSC cultures ( Supplementary  Fig. 14a,b) . Targeting of BMI1 or EZH2 protein levels and chromatin effects was confirmed by immunoblot, measured by their respective modifications (H2K119Ub and H3K27me3). BMI1 depletion potently decreased cell viability of mesenchymal GSCs under stress, with modest or no effects on proneural GSCs (Supplementary Fig. 14c ). In contrast, EZH2 depletion did not sensitize GSCs to harsh growth conditions, suggesting that EZH2 is dispensable under stress. To further support these findings, forced BMI1 expression in proneural GSCs increased cell viability under stress without altering cell growth or tumorsphere formation in the absence of stress ( Supplementary  Fig. 14d-g ).
To determine the potential role of BMI1 in mediating in vivo tumor growth mimicking regional tumor growth, we performed an in vivo cell-mixing experiment with orthotopic co-implantation of BMI1-overexpressing mCherry + proneural GSCs and control GFP + proneural GSCs (Supplementary Fig. 14h ). BMI1 + cells showed accelerated disease progression, as compared to GFP + control proneural GSCs (Supplementary Fig. 14i ). BMI1-overexpressing cells preferentially localized to CA9 + hypoxic regions in the subsequent brain tumors (Supplementary Fig. 14j ), suggesting that BMI1 confers tumor cell fitness in the hypoxic niche. In line with the preferential expression of EZH2 in proneural cells, RNA interference using two nonoverlapping shRNAs against EZH2 preferentially reduced cell growth and tumorsphere generation of proneural GSCs (Fig. 4a,b) . Reciprocally, BMI1 depletion preferentially reduced mesenchymal GSC cell growth and tumorsphere formation (Fig. 4a,b) , demonstrating differential sensitivity to PRC depletion based on molecular subtypes. Collectively, these results support a context-specific role for BMI1, suggesting that differential utilization of PRCs may contribute to divergent subtypespecific niche adaptation and associated poor prognosis.
To leverage our findings for clinical application, we examined the sensitivity of GSC subtypes to PTC596 (BMI1-i), a BMI1 inhibitor, or EPZ6438 (EZH2-i), an EZH2 inhibitor. Mesenchymal GSCs displayed preferential sensitivity to BMI1-i treatment; the half-maximal inhibitory concentration (IC 50 ) of BMI1-i was fourfold lower in mesenchymal GSCs than in proneural GSCs and a neural precursor line (Fig. 4c,d) , proneural GSCs were generally more sensitive to EZH2-i treatment. Differential sensitivity was confirmed by comparing the mean IC 50 of BMI1-i and EZH2-i in proneural and mesenchymal GSCs, respectively (Supplementary Fig. 15a ). To determine combinatorial efficacy, we interrogated the effects of a range of concentrations of each inhibitor against two proneural and two mesenchymal patient-derived GSC cultures (Supplementary Fig. 15b,c) . While we did not observe a synergistic interaction, the combination of low, clinically achievable concentrations of BMI1 and EZH2 inhibitors completely blocked tumorsphere formation and eradicated GSCs (Fig. 4e) . As all drugs may have off-target effects, we validated the subtype-specific effect of BMI1 and EZH2 inhibitors on cell viability and tumorsphere-forming ability with structurally unrelated inhibitors: PTC209 (another BMI1 inhibitor) and DZNep (another EZH2 inhibitor) (Supplementary Fig. 16 ).
Systemically delivered drugs against brain tumors must achieve intracranial delivery, as even contrast-enhancing gliomas, representing a disrupted blood-tumor barrier, usually have regions of tumor protected by a barrier. To augment the brain penetration of the EZH2-i, we leveraged a previously developed approach using a combination with the dual ABCCB1 and ABCG2 inhibitor GW120918 (Elacridar) 33 . Measurement of the plasma and brain levels of BMI1-i after treatment indicated that at least 20% of the BMI1-i in blood penetrates into the brain (Supplementary Fig. 17a,b) . To determine whether the concentrations achievable in the brain were efficacious, we plotted the concentrations of BMI1 and EZH2 inhibitors (PTC596 and EPZ6438, respectively) measured in the brain against the combinational efficacy studies on four different subtype GSCs, consistent with an 80% in vitro inhibitory concentration 33 ( Supplementary  Figs. 16d and 17a,b) . Pharmacodynamics analysis of PTC596 and EPZ6438 against intracranial models over a time course confirmed that BMI1 and EZH2 inhibitors specifically attenuated H2K119Ub and H3K27me3 in tumor tissues obtained from orthotopic tumors (Supplementary Fig. 17c-e) .
Leveraging evidence that the BMI1 and EZH2 inhibitors penetrate into the brain, we examined the therapeutic effects of PTC596 and EPZ6438 on mice bearing intracranial tumors derived from proneural GSCs, mesenchymal GSCs or a mixture of both ( Fig. 5a and Supplementary Fig. 18a ). Though the bioluminescent signal was near the limit of detection, bioluminescence imaging confirmed that antitumor effects of EZH2 inhibition were more effective against proneural cells than mesenchymal cells, whereas BMI1 inhibition showed the opposite effect, with combined therapy being more effective ( Fig. 5b and Supplementary Figs. 18b-e and 19) . To address the in vivo cellular effects of the EZH2 or BMI1 inhibitor treatments, we xenografted a combination of mCherry + proneural and GFP + mesenchymal GSCs, treated with vehicle control or the inhibitors (alone or in combination), and analyzed the tumors (Supplementary Fig. 20) . In mCherry + proneural cells, EZH2-i treatment specifically reduced the number of cells with the PRC2 mark H3K27me3, the GSC marker CD15 and the cell proliferation marker Ki67, whereas mesenchymal cells showed much more modest changes. In contrast, BMI1-i treatment ablated the mesenchymal population. The combination of the BMI1 and EZH2 inhibitors had effects on each marker in both compartments. Cell apoptosis, as measured by active caspase-3, and senescence, as measured by senescence-associated β-galactosidase, did not show substantial changes with any of the therapies tested. Further, we quantified the residual number of each fluorescently labeled tumor cell population after each therapy, confirming preferential activity of each inhibitor of the specific tumor subtype and superiority of combined treatment (Fig. 5c) . These in vivo results translated into superior survival with combined treatment (Fig. 5d-f) , indicating that the combinatorial inhibition of BMI1 and EZH2 is an effective treatment strategy for heterogeneous microenvironment-dependent subtype glioblastoma.
DISCUSSION
Tumor cell heterogeneity arises from variation in genetics, epigenetic cell state and microenvironment. Single-cell RNA-seq of gliomas demonstrated intratumoral variation in transcription profiles with a fraction of proliferating cells that express stem cell programs 13 .
Multiple GSC clones can be derived from a single patient 14, 34, 35 . Our results refine these observations by linking spatially defined, radiographic features to GSCs with specific transcriptional signatures and response to targeted therapies. We recently reported that mesenchymal GSCs show DNA hypomethylation associated with reduced availability of methionine and hypoxic induction of methyltransferases that deplete methyl donors 36 , suggesting that regional epigenetic regulation could extend to DNA methylation. Here we find that stress responses may select for different dependencies on PRCs, with BMI1, a core component of PRC1, promoting cellular survival in areas of low oxygen and nutrient availability. Collectively, these findings support a model in which hypoxia promotes the survival of mesenchymal GSCs by repressing expression of a BMI1 E3 ligase, RNF144A, which results in an increase of BMI1 protein stability. Like neural stem cells, GSCs receive maintenance cues from their microenvironment, but rather than being passive recipients of these cues, they actively remodel their environment through induction of angiogenesis and other features 37 . As we and others have found that hypoxia, acidic stress and nutrient restriction promote GSC maintenance, the RNF144A-BMI1 regulatory mechanism may empower GSCs to reside in stressful microenvironments.
The significance of epigenetic diversity in tumors is supported by genetic observations that 40% of glioblastomas harbor mutations in epigenetic regulators, including BMI1 and EZH2 (ref. 38) . Epigenetic dysregulation may induce neoplasia and be amenable to therapeutic targeting, but likely does not adhere to a simple dichotomization of mutations into oncogenes and tumor suppressors, rather permitting cellular plasticity to accelerate tumor evolution. IDH1 mutations transform astrocytes through modulation of DNA methylation 39 . Mutant IDH1 inhibitors attenuate tumor growth of gliomas harboring IDH1 mutations 40 . Pediatric glioblastomas are commonly driven by mutations in variant histones, which lead to alterations in DNA methylation and transformation [41] [42] [43] . Epigenetic regulators may be particularly effective targets, as oncogenic pathways converge on the epigenome to maintain neoplasia 44 . BMI1 regulates tumor initiation and growth in a genetically engineered murine model of glioblastoma and human stem-like glioma lines [45] [46] [47] [48] . BMI1 binds and regulates the promoters of numerous genes, including TGF-β, which has been strongly linked to a mesenchymal phenotype 49 . Targeted therapies against BMI1 have shown preclinical efficacy in a number of cancer types, with effects against cancer stem cells 50 . EZH2 has also been investigated as a cancer therapeutic target, with numerous studies suggesting potential therapeutic benefit against adult and pediatric high-grade gliomas [51] [52] [53] [54] [55] [56] . The dynamic interchange of elements between PRC1 and PRC2 suggests that the roles of BMI1 and EZH2 are not biochemically interchangeable but may permit plasticity of cell state under different microenvironmental conditions. Our results support a model in which GSCs are present in different niches with differential utilization of BMI1 and EZH2 (Supplementary Fig. 21) . Thus, differential region-specific dependency on epigenetic modifiers may inform the development of a combinatorial treatment approach that could collapse intratumoral heterogeneity and limit adaptation to cancer therapeutics.
Little is known about RNF144A beyond its enzymatic function. RNF144A is an E3 ligase for DNA-PKcs 33 . Interrogation of the cBio Portal database shows that several cancer types have RNF144A mutations or amplifications, including prostate, breast, uterine and lung (data not shown). One patient with low-grade glioma had a missense mutation, and the TCGA glioblastoma data included one patient with a deletion, one with an amplification and one with a nonsense mutation (data not shown). Prior reports investigating BMI1 mRNA expression support increased expression in proneural tumors, but our results demonstrate that BMI1 activity does not correlate with BMI1 mRNA levels and that BMI1 protein levels are higher in mesenchymal tumors than proneural tumors. RNF144A post-translational regulation of BMI1 is a previously unknown mechanism of BMI1 regulation in glioblastoma and reveals a limitation of transcriptional target discovery. Moreover, the clinical relevance of the RNF144A and BMI1 activation signatures inform biomarker development for BMI1 inhibitors.
Our results demonstrate the efficacy of combined inhibition of BMI1 and EZH2, but the efficacy was not absolute. Though monotherapy against either PRC component hindered tumor growth near the limits of detection, combinatorial therapy against both proneural and mesenchymal tumors achieved the most effective tumor control. Glioblastoma cells can undergo molecular subtype transitions under the influence of different tumor microenvironment that may lead to different effects between in vitro and in vivo experiments by BMI1 and EZH2 inhibitor treatments. It would be interesting to determine how interconversion between different pools of GSCs may support adaptive resistance to targeted therapies. Our findings suggest that epigenetic therapies against heterogeneous tumors are likely to be more effective in combination than alone. Both BMI1 and EZH2 contribute to resistance to radiation and chemotherapy, suggesting that our dual targeting strategy may be useful in combination with conventional therapies 54, 57, 58 . Similarly to our prognostic findings, the combined expression of BMI1 and EZH2 in bulk tumor may have greater negative prognostic significance than either target alone 59 . As single tumors may contain different pools of GSCs, we advocate considering not only combined targeting of epigenetic processes, which may prevent the plasticity of cell state transitions, but also GSC pools.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
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ONLINE METHODS
Human glioblastoma specimens. Excess tumor tissues were collected from glioblastoma patients from whom informed consent was obtained in accordance with approved Institutional Review Board protocols from Cleveland Clinic, Duke University, or University Hospitals-Cleveland Medical Center (UH-CMC). At UH-CMC, the surgeon selected only tumors with significant quantities of enhancing tumor; peritumor regions, which were non-enhancing on T1 weighted MRI with gadolinium but hyperintense on FLAIR imaging and thought to contain infiltrating tumor cells; and necrotic avascular regions in the center of the tumor (enhancing region, enhancing margin, and necrotic region respectively as indicated in Fig. 1) . Prior to surgery, the surgeon obtained volumetric imaging of the patient and pre-selected distinct areas of enhancing, necrotic and invading tissue to sample according to his surgical strategy. In the operating room, after co-registration was confirmed to be accurate (BrainLab Stealth), the surgeon then sampled regions from these distinct areas using stereotactic techniques at the beginning of the procedure. These distinct specimens from different anatomic regions of each tumor were then processed separately and analyzed as indicated below.
Cells and culture condition. Fresh CD15 + GSCs from CW2451, CW2472, and CW2473 glioblastoma primary specimens were isolated with magnetic columns (MACS, CD15 microbeads, Miltenyi Biotec, 130-046-601), and their self-renewal ability, functionally validated by limited dilution assay (LDA). Cultures enriched or depleted for GSCs (PN1919, PN3691, PN1914.2, MES3565, MES738, and MES3128) were isolated from surgical specimens or xenografts and functionally validated as previously described [5] [6] [7] . Functional assays included prospective enrichment of stem cell marker expression, sphere formation, and in vivo tumor formation. Cellular contamination was ruled out by serial short tandem repeat (STR) analysis and mycoplasma testing. Molecular subtyping was performed by either expression array or RNA sequencing. Normal neural progenitor cells (NPC1 (NHP1), NPC2 (NPC16357), and NPC3 (NPC17893)) and GSCs were maintained in neurobasal medium with B27 (without vitamin A, Invitrogen), basic fibroblast growth factor (20 ng/ml) and epidermal growth factor (20 ng/ml).
Quantitative RT-PCR. Total RNA was isolated with the RNeasy kit (Qiagen) and reverse-transcribed into cDNA using the aScript cDNA SuperMix (Quanta Biosciences). Real-time PCR was performed on an Applied Biosystems 7900HT cycler using SYBR-green Mastermix (SA Biosciences). Expression values were normalized to 18S. Gene-specific primers as follows: 18S forward 5′-TGCATGGCCGTTCTTAGTTG-3′ and reverse 5′-AGTTAGCATGCCAGAGTCTC-3′; DLL3 forward 5′-CCT GCGCGCTGAATGTC-3′ and reverse 5′-CATCGAAACCTGGAGAGA GG-3′; OLIG2 forward 5′-CTGGCGTCCGAGTCCAT-3′ and reverse 5′-CCTGAGGCTTTTCGGAGC-3′; ASCL1 forward 5′-CAACGCCA CTGACAAGAAAG-3′ and reverse 5′-GGAGCTTCTCGACTTCACCA-3′; CD133 forward 5′-TTTTGGATTCATATGCCTTCTGT-3′ and reverse 5′-ACCCATTGGCATTCTCTTTG-3′; FOXO3 forward 5′-GGTGAATT TCCAATCATCAGC-3′ and reverse 5′-CGAGCTATAGACACCCTG AATG-3′; MBP forward 5′-AGGTCTCGTTCCGTGCTG-3′ and reverse 5′-GCCACCATCCCTTGTGAG-3′; GABRB2 forward 5′-GGAACAATA CTACCTAAGGACAA-3′ and reverse 5′-AGTTTGCAACTTAAATCTC AGTT-3′; PDGFA forward 5′-GACCGATCCTCAAGCATCTC-3′ and reverse 5′-AAGGACAAGCGGACAAAATG-3′; NES forward 5′-GCAGCAG GAAATATGGGAAG-3′ and reverse 5′-TCTCATGGCTCTGGTTTTCC-3′; EGFR forward 5′-CTCCGTTTCTTCTTTGCCCAG-3′ and reverse 5′-GCA CAAGCCACAAGTGTTCC-3′; AKT2 forward 5′-ACATCATCTCGTA CATGACCAC-3′ and reverse 5′-CTCTGCAAAGAGGGCATCAG-3′; CD44 forward 5′-TGACACTGTCCAAAGGTTTTC-3′ and reverse 5′-TCA CTAATAGGGCCAGCCTC-3′; YKL40 forward 5′-CCAAGGAGCCAA ACATCCTA-3′ and reverse 5′-GAAGGGGAAGTAGGATAGGGG-3′; TIMP1 forward 5′-TGGTAACTCTTTATTTCATTGTCCG-3′ and reverse 5′-CTGAAAAGGGCTTCCAGTCC-3′; and TGFβ1 forward 5′-GCCAGATCCTGTCCAAGCTG-3′ and reverse 5′-GGTGACCTCCT TGGCGTAGTA-3′; CA9 forward 5′-ACCTGGTGACTCTCGGCTA CAG-3′ and reverse 5′-CAGCCAGGCAGGAATTCAGC-3′; GLUT3 forward 5′-AGCTCTCTGGGATCAATGCTGTGT-3′ and reverse 5′-ATGGTGGCATAGATGGGCTCTTGA-3′; GLUT1 forward 5′-TCATCGTGGCTGA ACTCTTC-3′ and reverse 5′-GATGAAGACGTAGGGACCAC-3′; HIF1α forward 5′-CCTATGTAGTTGTGGAAGTTTTGC-3′ and reverse 5′-ACTA GGCAATTTTGCTAAGAATG-3′; MCT1 forward 5′-TGTAATCTACCAGTG GTGCTC-3′ and reverse 5′-AACCTACTTCTTTCCCCCATC-3′; MCT4 forward 5′-GGGTCATCACTGGCTTGGGT-3′ and reverse 5′-GGAACACGGGACTG CCTGC-3′; LDH5 forward 5′-TGCTGTACGTACTGCATTTGC-3′ and reverse 5′-ATCCCAGGATGTGACTCACTG-3′; CD31 forward 5′-AAGGCCA GATGCACATCC-3′ and reverse 5′-TTCTACCCAACATTAACTTAGCAGG-3′; VEGFR2 forward 5′-TAGCATGTCTTATAGTCATT-3′ and reverse 5′-CACT CTCTGAATGATTATTA-3′; CD34 forward 5′-CCGTCATTGAAACCAGG-3′ and reverse 5′-TCATAGCCCAGATCAGCTC-3′; ACTIN forward 5′-AGAAAAT CTGGCACCACACC-3′ and reverse 5′-AGAGGCGTACAGGGATAGCA-3′; VEGFB forward 5′-CCATCTCTTTTATCAGGGTTGG-3′ and reverse 5′-CTCTG TGCAAGTAAGCATCTTACA-3′.
Western blot analysis and immunoprecipitation assay. Cells were collected and lysed in IP Lysis buffer (Thermo Scientific) containing phosSTOP phosphatase inhibitor cocktail (Roche) and protease inhibitor cocktail (Sigma) and separated by 12% SDS-PAGE (NuPAGE Bis-Tris gel, Invitrogen) and transferred to PVDF membranes (Millipore). Membranes were blocked with 5% (wt/vol) nonfat milk in PBS + Tween-20 (0.5% vol/vol) and probed with primary antibodies against BMI1 (1:1,000, Abcam, ab126783), H2K119Ub (1:1,000, Cell signaling, #8240S), CD44 (1:1,000, BD Biosciences, 550392), YKL40 (1:1,000, Abcam, ab86428), EZH2 (1:1,000, BD Biosciences, 612667), H3K27Me3 (1:1,000, Millipore, 07-689), OLIG2 (1:1,000, R&D system, AF2418), SOX2 (1:1,000, R&D system, AF2018), RNF144A (1:500, Abcam, ab89260), Ub (1:5,000, Santa Cruz, sc-9133), tubulin (α-tubulin,1:10,000, Sigma-Aldrich, T6074), and ACTIN (β-actin,1:10,000, Sigma-Aldrich, A1978). BMI1-RNF144A interaction and BMI1 polyubiquitination were detected by Pierce Crosslink magnetic IP and Co-IP kit (Thermo Scientific). For the ubiquitination assays, cells were treated with Lactacystin (5 µM or 10 µM; Sigma) for 5 h before collection. BMI1 polyubiquitination was quantified by ImageJ.
Immunofluorescence and b-gal staining. 10-µm thick slides of deidentified frozen multiregional samples (glioblastoma patient CW1757 according T1-weighted MRI images) and PN3691 (VEC/BMI1) xenografted frozen brain tissue were fixed in 4% paraformaldehyde and immunolabeled using primary antibodies to SOX2 (1:500, R&D system, AF2018), CD44 (1:100, BD Biosciences, 550392), vWF (1:500, Millipore, AB7356), CA9 (1:100, Genetex, GTX70020), H3K27me3 (1:1,000, Millipore, 07-689), H2AK119Ub (1:500, Cell Signaling, 8240S), CD15 (1:100, Millipore, MAB4301), Ki67 (1:100, Dako, M7240), active CASPASE3 (1:100, Cell Signaling, 9661S) and the secondary fluorescence-labeled antibodies. Nuclei were counterstained with DAPI. Immunofluorescence images were taken by a Leica TCS SP5 Confocal Microscope or a Leica SCN400 Slide Scanner. A senescence β-galactosidase staining kit (Cell Signaling, 9860S) was used to detect senescent cells in tumor tissues, the phase-contrast light images were captured by Leica DM4000 B microscope.
Tissue microarray (TMA) and immunohistochemistry. 5-µm thick slides of deidentified paraffin-embedded tissue microarrays (TMAs) were constructed from glioma after obtaining Ohio State University Institutional Review Board Approval. A total of 96 cases were arrayed on the TMA block, including 15 non-neoplastic controls (cortical dysplasias), 16 grade II glioma cases, 27 grade III gliomas, and 38 grade IV glioblastomas. Tissues too small and/or crushed on the TMA were eliminated from analysis after immunohistochemistry staining with anti-BMI1 (1:50, Abcam, ab126783), anti-EZH2 (1:100, BD Biosciences, 612667), anti-CD44 (1:100, BD Biosciences, 550392), anti-OLIG2 (1:100, R&D system, AF2418), and secondary HRP-conjugated antibodies. The TMA images were taken by a Leica SCN400 Slide Scanner. Overall staining on TMA was scored as negative (−) or positive (+) compared to nonneoplastic controls. PN3691 (with or without treatment with BMI1 or EZH2 inhibitors) xenografted brain tissues were fixed in 4% PFA and stained with anti-H2K119Ub (1:100, Cell Signaling, 8240S), anti-H3K27me3 (1:1,000, Millipore, 07-689), and secondary HRP-conjugated antibodies. Nuclei in nature research | life sciences reporting summary
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See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Microsoft Excel, Matlab R2016a, R v3.3.0, GraphPad Prism, HOMER, TopHat2, BedTools, Cufflinks
For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
-All cell lines and constructs are available to anyone in the community through appropriate material transfer agreements.
-BMI1 inhibitors PTC596 and PTC209 are available for distribution through PTC Therapeutics (South Plainfiled, NJ, USA).
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). 10. Eukaryotic cell lines a. State the source of each eukaryotic cell line used.
-All GSC models were derived from disassociation of patient specimens.
-293T cells used to produce virus for transduction were obtained from the CCF/LRI cell culture core.
b. Describe the method of cell line authentication used. All GSC models were verified for purity using STR analysis.
c. Report whether the cell lines were tested for mycoplasma contamination.
All cell lines were regularly tested for mycoplasma contamination. For all animal experiments were performed with 3-4 week-old male and female NSG mice
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
All patients whose excess tissue specimens were analyzed in this study were informed and consented according to respective IRB protocols approved by the Cleveland Clinic Foundation, University Hospitals, and The Ohio State University Medical Center.
